Thermo Fisher Bioproduction Insights

31. Purification Of Complex mAb Modalities: Ask The Specialists 7/16/2025

    Traditional mAb purification methods often fall short with complex modalities. Discover how experts tackle new impurities and structural complexities to enhance therapeutic antibody purification.

32. Aiming For Success In Early mAb Process Development And Beyond 7/15/2025

    Developing a monoclonal antibody (mAb) requires strict quality compliance. Building on a strong foundation from the start with a quality by design (QbD) approach is key for success and minimizing variability.

33. The Value Of Peptones For Cost-Effective Vaccine Manufacturing 6/16/2025

    Peptones offer a strategic solution to key biomanufacturing challenges by enhancing cell culture performance, improving yields, and reducing production costs.

34. Enabling Development Of Scalable, Personalized Cell Therapies For Solid Tumor Treatments 6/16/2025

    Harnessing the body’s own immune system, researchers are developing personalized cell therapies to target solid tumors, using a patient’s unique mutations to create powerful, individualized treatments.

35. Manufacturing CAR T Cell Therapies: Challenges, Insights And Solutions 6/16/2025

    Manufacturing patient-specific cell therapies is a complex, multi-step process. Addressing key hurdles in production time, scalability, and cost is crucial to making these vital treatments more accessible.

36. Raw Material Considerations For Cell Therapies 6/16/2025

    For cell therapy developers, selecting appropriate raw materials is a significant challenge. Examine key considerations for mitigating risk and aligning with current regulatory expectations.

37. Next-Gen Biomanufacturing: Process Intensification For mAb Production 6/13/2025

    Intensified processes, omics-driven media, and advanced bioreactors can boost efficiency and scalability in mAb production.

38. Improved T Cell Expansion Using Closed, Automated Stirred-Tank Bioreactors 6/10/2025

    A shift from traditional rocking motion systems to stirred-tank bioreactors can enhance T cell expansion, offering greater scalability and more intimate process control.

39. Comparing Serum-free To Serum-Supplemented Media 6/9/2025

    Reducing serum in vaccine manufacturing is a key consideration for lowering costs and improving supply security. We compare performance in serum-free versus serum-supplemented media.

40. A Temperature-Stable Replacement For Animal Trypsin In Cell Dissociation Applications 6/9/2025

    Improve cell dissociation with a gentle, recombinant enzyme. This temperature-stable protease shows dissociation kinetics similar to porcine trypsin but with lower cell toxicity and greater overall purity.